JP2007522176A5 - - Google Patents

Download PDF

Info

Publication number
JP2007522176A5
JP2007522176A5 JP2006552565A JP2006552565A JP2007522176A5 JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5 JP 2006552565 A JP2006552565 A JP 2006552565A JP 2006552565 A JP2006552565 A JP 2006552565A JP 2007522176 A5 JP2007522176 A5 JP 2007522176A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
hydrogen
alkenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007522176A (ja
JP5001012B2 (ja
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed filed Critical
Priority claimed from PCT/EP2005/001449 external-priority patent/WO2005077950A2/en
Publication of JP2007522176A publication Critical patent/JP2007522176A/ja
Publication of JP2007522176A5 publication Critical patent/JP2007522176A5/ja
Application granted granted Critical
Publication of JP5001012B2 publication Critical patent/JP5001012B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552565A 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤 Expired - Fee Related JP5001012B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0403282.7 2004-02-14
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0423562.8 2004-10-22
GB0428375.0 2004-12-24
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds
PCT/EP2005/001449 WO2005077950A2 (en) 2004-02-14 2005-02-10 Medicaments with hm74a receptor activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008030344A Division JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Publications (3)

Publication Number Publication Date
JP2007522176A JP2007522176A (ja) 2007-08-09
JP2007522176A5 true JP2007522176A5 (enExample) 2008-04-03
JP5001012B2 JP5001012B2 (ja) 2012-08-15

Family

ID=34864831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006552565A Expired - Fee Related JP5001012B2 (ja) 2004-02-14 2005-02-10 Ｈｍ７４ａ受容体活性を有する薬剤
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008030344A Expired - Fee Related JP5020848B2 (ja) 2004-02-14 2008-02-12 Ｈｍ７４ａ受容体活性を有する薬剤

Country Status (25)

Country Link
US (5) US7713982B2 (enExample)
EP (1) EP1781657B1 (enExample)
JP (2) JP5001012B2 (enExample)
KR (1) KR101100601B1 (enExample)
CN (2) CN101863888B (enExample)
AR (1) AR047669A1 (enExample)
AU (1) AU2005212816C1 (enExample)
BR (1) BRPI0507604A (enExample)
CA (1) CA2556073C (enExample)
CY (1) CY1114022T1 (enExample)
DK (1) DK1781657T3 (enExample)
ES (1) ES2406732T3 (enExample)
HR (1) HRP20130406T1 (enExample)
IL (1) IL177051A (enExample)
MA (1) MA28357A1 (enExample)
MY (1) MY148937A (enExample)
NO (1) NO337281B1 (enExample)
NZ (1) NZ548496A (enExample)
PE (1) PE20060317A1 (enExample)
PL (1) PL1781657T3 (enExample)
PT (1) PT1781657E (enExample)
SG (1) SG157242A1 (enExample)
SI (1) SI1781657T1 (enExample)
TW (1) TWI350289B (enExample)
WO (1) WO2005077950A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL206890B1 (pl) * 1999-11-12 2010-10-29 Biogen Idec Ma Pochodna bicykloalkilopuryny, jej zastosowanie i kompozycja leku
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
EP1603585A2 (en) 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
SI1781657T1 (sl) * 2004-02-14 2013-07-31 Glaxosmithkline Intellectual Property Development Limited Zdravila z aktivnostjo na receptor hm74a
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
AU2006247695B2 (en) 2005-05-17 2012-08-09 Merck Sharp & Dohme Corp. Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006259137B2 (en) * 2005-06-14 2010-04-01 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
HRP20110295T1 (hr) 2005-06-28 2011-05-31 Merck Sharp & Dohme Corp. Agonisti receptora niacina, smjese koje sadržavaju takve spojeve i postupci liječenja
EP1912992A1 (en) * 2005-08-10 2008-04-23 SmithKline Beecham Corporation Xanthine derivatives as selective hm74a agonists
CN101400682A (zh) * 2006-01-20 2009-04-01 先灵公司 治疗异常脂血症的杂环烟酸受体激动剂
MX2008014689A (es) * 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
CA2656039A1 (en) 2006-06-23 2007-12-27 Incyte Corporation Purinone derivatives as hm74a agonists
AR061626A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
CA2680775A1 (en) 2007-03-23 2008-10-02 F. Hoffmann-La Roche Ag Aza-pyridopyrimidinone derivatives
PL2370440T3 (pl) * 2008-12-08 2015-05-29 Glaxosmithkline Llc Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
BR112017016065A2 (pt) * 2015-01-30 2018-04-03 Shanton Pharma Co., Ltd. prevenção ou tratamento de ácido úrico ou doença gotosa
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
MX2019008230A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
AU2024229006A1 (en) * 2023-02-27 2025-09-18 Shanton Pharma Pte. Ltd. Crystal form of 8-chloro-3-pentyl-3,7-dihydro-1h-purin-2,6-dione compound and preparation method therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
ATE230990T1 (de) 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
EP0746557A4 (en) * 1994-02-18 1997-05-02 Cell Therapeutics Inc INTRACELLULAR SIGNALING MEDIATORS
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
KR100502757B1 (ko) * 1999-08-31 2005-07-22 반더빌트유니버시티 Ａ２ｂ 아데노신 수용체의 선택적인 길항제
EP1305328A2 (en) * 2000-07-21 2003-05-02 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
JP2004512278A (ja) * 2000-09-19 2004-04-22 ノビムーヌ　ソシエテ　アノニム 新規な免疫調節剤、免疫阻害剤、及び抗炎症剤としてのスタチン（ＨＭＧ−ＣｏＡリダクターゼ阻害剤）
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
HU230384B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
US20040254224A1 (en) * 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
SI1781657T1 (sl) 2004-02-14 2013-07-31 Glaxosmithkline Intellectual Property Development Limited Zdravila z aktivnostjo na receptor hm74a
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
EP1912992A1 (en) 2005-08-10 2008-04-23 SmithKline Beecham Corporation Xanthine derivatives as selective hm74a agonists
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
PL2370440T3 (pl) * 2008-12-08 2015-05-29 Glaxosmithkline Llc Bezwodnik 2-amino-2-(hydroksymetylo)-1,3-propanodiolu 8-chloru-3-pentylo-3,7-dihydro-1H-puryno-2,6-dionu do leczenia chorób
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Similar Documents

Publication Publication Date Title
JP2007522176A5 (enExample)
CA2556073A1 (en) 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators
JP7640481B2 (ja) 代謝機能不全によって引き起こされる腫瘍の治療
US11013722B2 (en) Therapeutic agent for dyslipidemia
HRP20100725T1 (hr) Derivati ksantina kao selektivni agonisti hm74a
JP2004522714A5 (enExample)
JP2007502263A5 (enExample)
JP2015164964A5 (enExample)
JP2011512856A5 (enExample)
JP2011514379A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP2007502264A5 (enExample)
JP2012529434A5 (enExample)
US9458093B2 (en) Compositions for the treatment of hypertension and/or fibrosis
KR20110021692A (ko) 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
CN1454054A (zh) 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进
CN101823956B (zh) 非诺贝特酸二异丙胺盐、其制备方法, 药物组合物及其用途
EP2945618A1 (en) Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
RU2742418C1 (ru) Лекарственные формы, содержащие оксалатные соли тенелиглиптина и их сольваты
B Ghatak et al. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus
RU2006132925A (ru) Новые соединения
JP2012511028A5 (enExample)
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
JP2020520904A5 (enExample)
WO2011141419A1 (en) Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof
AU2020408557A1 (en) Use of lemborexant for treating insomnia